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Purpose/Objective: Loco-regional recurrences remain 
frequent in locally advanced non-small cell lung cancer 
(NSCLC) patients and are predominantly located in the area 
of the primary tumor. Improved tumor control might be 
accomplished by dose-escalation and dose-redistribution. The 
PET-boost trial (NCT01024829) is an ongoing randomized 
phase II trial investigating individualized accelerated dose-
escalation to the entire primary tumor (arm A) or 
redistributed to regions of high FGD-uptake within the 
primary tumor (arm B). We present a planned interim 
analysis of the toxicity of 63 randomized patients. 
Materials and Methods: Patients with NSCLC stage IB-III, a 
primary tumor (PT) ≥4 cm and a SUVmax ≥5 are treated with 
chemo-radiation or radiotherapy alone. Treatment plans are 
designed using a pre-treatment FDG-PET-CT-scan with similar 
dose limits to OAR as in conventionally treated patients. If 
normal tissue constraints allow dose-escalation using an 
integrated boost ≥72 Gy in 24 fractions to the PT and with 
equal mean lung dose for both study arms, a patient is 
randomized to arm A or arm B. Involved lymph nodes are 
treated to a fractionation dose of 66 Gy in 24 fractions. 
Toxicity is scored according to the CTCAEv3.0 criteria. 
Endpoints are local progression-free survival at 1 year, 
toxicity, overall survival and quality of life. 
Results: From April 2010 to March 2014, 32 patients were 
randomized to arm A and 31 patients to arm B. Forty-eight 
patients received concurrent chemo-radiotherapy. Median 
follow-up was 25.5 months. The mean PT volume in arm A 
was 123.4cc and in arm B 181.5cc. Mean prescribed dose to 
the planning target volume of the primary tumor was 3.3 Gy 
(range 3.0-4.0 Gy) in arm A and 3.9 Gy (range 3.2-5.4 Gy) in 
arm B. Grade ≥3 dysphagia and dyspnea during treatment 
occurred in 7 and 2 patients (11 and 3%). Grade ≥3 
esophagitis and pneumonitis after treatment was seen in 11 
and 6 patients (17.5% and 9.5%). Hematologic toxicity grade 
≥3 was observed in 5%. Four out of 63 patients (6.3%) died 
due to pulmonary hemorrhage.  
Conclusions: This interim toxicity analysis of the randomized 
phase II PET-boost trial shows that dose-escalation is feasible 
in 63 randomized patients. The toxicity observed during and 
after treatment shows no excess or unexpected toxicity.  
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Purpose/Objective: The prognostic value of standardized 
uptake value (SUV) distribution of the fluorine-18 labeled 
glucose analog (FDG), has been widely studied for the 
primary tumor in non-small cell lung cancer (NSCLC) patients. 
However, nodal stage determines treatment choice and is 
related to disease progression and its capability to 
metastasize. We hypothesize that more PET-related 
prognostic information can be extracted from affected 
hilar/mediastinal lymph nodes than in the primary tumor. 
Therefore, we analyzed the SUV distribution and volume of 
the primary tumor and affected lymph nodes prior to 
radiotherapy. 
Materials and Methods: A cohort of 352 stages I-III NSCLC 
patients referred for primary (chemo)radiotherapy was 
included. The gross tumor volume of the primary tumor 
(GTVprim) and the metastatic lymph nodes (GTVln) had been 
manually delineated for treatment planning purposes. The 
nodal positive subset of patients (272) was selected for a 
comparison analysis based on volume and SUV descriptors 
(maximum, mean and peak), as derived from both the 
primary tumor and the affected lymph nodes, of the pre-
radiotherapy PET scan. The prognostic value of each of the 
metrics to overall survival (OS), recorded from start of 
radiotherapy until last day of follow-up or death by any 
cause, was evaluated through a Cox Proportional Hazards 
regression. 
Results: We first compared the distribution of volume and 
common SUV descriptors of the primary tumor for N=0 (80) 
and N+ (272) NSCLC patients. The GTVprim of patients without 
affected lymph nodes was metabolically more active (SUVmax 
= 13 ± 6.3; p<0.01, and SUVpeak = 10.3 ± 5.1; p=0.02) and 
larger (volume = 127.3 ± 235.4; p < 0.01) than the GTVprim of 
patients with affected lymph nodes. 
Mean ranks difference (Wilcoxon test) of volume and SUV 
descriptors of both GTVprim and GTVln was conducted for the 
nodal positive subset of patients, for which statistically 
significant (p<0.001) differences between metrics derived 
from the two structures could be shown (see table).  
The prognostic value of each of the metrics to OS was 
evaluated through a Cox Proportional Hazards regression. 
None of the metrics derived from the primary tumor were 
associated with OS in our cohort. However, the same metrics, 
extracted from the involved lymph nodes, were prognostic 
for survival with mean SUV showing the strongest correlation 
with OS (HR=1.14, p < 0.01). Also, tumor load, defined as 
GTVprim + GTVln showed a statistically significant correlation 
with OS. Currently, a multivariate analysis and collection of 
an external dataset for validation is ongoing. 
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Conclusions: The most common SUV descriptors as well as 
the volume of the involved lymph nodes of NSCLC patients 
are significant prognostic factors for overall survival for 
NSCLC. Likelihood of a worse prognosis increases with an 
increase of the mean SUV of the nodes. This is consistent 
with our hypothesis that there is more PET-related prognostic 
information in the nodes compared to the primary tumor.  
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) is 
the treatment of choice in medically inoperable patients with 
stage I NSCLC. Today, SBRT is used with increasing frequency 
for pulmonary metastases: however, dose prescriptions are 
adapted from primary NSCLC experiences without their 
validation for metastases. It was therefore the aim of this 
study to analyze a potential dose-effect relationship for local 
tumor control in SBRT for pulmonary metastases and compare 
results to SBRT for stage I NSCLC. 
Materials and Methods: This retrospective multi-institutional 
study is based on 582 and 964 patients treated with SBRT for 
stage I NSCLC and pulmonary metastases at 13 centres; only 
patients with follow-up >6 months were analyzed resulting in 
399 and 525 patients, respectively. Patients with primary 
NSCLC and pulmonary metastases were treated with a 
median of 3 (range 1-17) and 3 (1-12) fractions to a total 
dose of 60Gy (range 19-86) and 55Gy (16-80) (maximum PTV 
dose at isocenter; PTV-max), respectively. BED was 
calculated using the LQ-model with α/β=10Gy resulting in 
PTV-max doses of 168Gy (48-263) and 138Gy (24-288) BED for 
primary NSCLC and metastases, respectively. Dose-effect 
models were compared using the second-order bias corrected 
Akaike Information Citerion (AICC). We used Bayesian logistic 
regression to estimate regression parameters and their 
standard errors. 
Results: Median tumor diameter was 2.6cm (0.8-4.8) and 
1.9cm (0.4-9.0) for patients with primary NSCLC and 
pulmonary metastases, respectively (p<0.001, Wilcoxon rank 
sum test); tumor diameter was lacking in 47% (primary 
NSCLC) and 12% (pulmonary metastases) of the patients. Most 
frequent histologies for pulmonary metastases were NSCLC 
(28%), colorectal (25%) and renal cell cancer (11%). Median 
follow-up was 19 months (6-139; primary NSCLC) and 16 
months (6-125; pulmonary metastases) (p=0.15). For 
pulmonary metastases, a strong dose response relationship 
was observed (evidence ratio 98.6), but only for PTV-max 
BED and not for the PTV encompassing BED; the latter is in 
contrast to findings from SBRT for primary NSCLC, where a 
strong evidence for a minimum PTV dose-effect was observed 
(Guckenberger et al. Radiother Oncol 2013). Overall, there 
was no difference in the dose response relationship between 
primary NSCLC and pulmonary metastases: the PTV-max BED 
required for 90% TCP was 176±17Gy and 167±18 Gy for 
primary NSCLC and pulmonary metastases, respectively. 
Conclusions: A significant dose-response relationship was 
observed in SBRT for pulmonary metastases with local tumor 
control as endpoint. The observed dose response relationship 
was not different to primary stage I NSCLC. We will, 
however, further investigate the influence of histology and 
tumor size on the dose-effect relationship in pulmonary 
metastases.  
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The incidence of breast cancer is rising in the elderly, 
reflecting the age related incidence of the disease and, in 
the UK, the impact  of  the breast screening programme. The 
evidence base for the role of postoperative radiotherapy (RT) 
after breast conserving surgery  in older patients has been 
limited, in part reflecting the historical exclusion of the 
elderly from randomised trials. Extrapolating outcomes from 
younger to older patients may not be valid. In older patients 
there are also competing risks of non breast cancer mortality. 
The Oxford overview (1) of over 10,000 women treated with 
breast conserving surgery with or without adjuvant 
radiotherapy shows that RT halves the risk of first recurrence 
(most of which are local). However the absolute reduction in 
risk of recurrence from RT is very modest in older good 
prognosis patients. The main source of level 1 evidence in 
older patients is the CALGB 9343 trial (1) which randomised 
over 700 women =/> 70 years with T1, NO,MO hormone 
receptor positive breast cancer treated by breast conserving 
